구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | systemic therapy as selected by the investigator (systemic therapy as selected by the investigator) Base Therapeutics (Shanghai) Co., …·NSCLC 23 trials |
|---|---|
Overview Program | systemic therapy as selected by the investigator |
Overview Company | Base Therapeutics (Shanghai) Co., Ltd. |
Overview Modality | CGT |
Overview Target | NSCLC |
Overview Indication | NSCLC |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Treatment for intermediate and advanced-stage hepatocellular carcinoma: does systemic therapy synergize the therapeutic efficacy of TACE?. Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage hepatocellular carcinoma (HCC), but its efficacy varies due to patient heterogeneity. Combining TACE with systemic therapies, such as targeted agents or immune checkpoint inhi… |
Clinical Safety signal | Treatment for intermediate and advanced-stage hepatocellular carcinoma: does systemic therapy synergize the therapeutic efficacy of TACE?. Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage hepatocellular carcinoma (HCC), but its efficacy varies due to patient heterogeneity. Combining TACE with systemic therapies, such as targeted agents or immune checkpoint inhi… |
Clinical Selected reported efficacy | ORR 44% |
Clinical Reported ORR | 44.0% |
Clinical Result source | ClinicalTrials.gov NCT04916002 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT04916002 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | systemic therapy as selected by the investigator (systemic therapy as selected by the investigator) Base Therapeutics (Shanghai) Co., …·NSCLC 23 trials |
|---|---|
Overview Program | systemic therapy as selected by the investigator |
Overview Company | Base Therapeutics (Shanghai) Co., Ltd. |
Overview Modality | CGT |
Overview Target | NSCLC |
Overview Indication | NSCLC |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Treatment for intermediate and advanced-stage hepatocellular carcinoma: does systemic therapy synergize the therapeutic efficacy of TACE?. Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage hepatocellular carcinoma (HCC), but its efficacy varies due to patient heterogeneity. Combining TACE with systemic therapies, such as targeted agents or immune checkpoint inhi… |
Clinical Safety signal | Treatment for intermediate and advanced-stage hepatocellular carcinoma: does systemic therapy synergize the therapeutic efficacy of TACE?. Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage hepatocellular carcinoma (HCC), but its efficacy varies due to patient heterogeneity. Combining TACE with systemic therapies, such as targeted agents or immune checkpoint inhi… |
Clinical Selected reported efficacy | ORR 44% |
Clinical Reported ORR | 44.0% |
Clinical Result source | ClinicalTrials.gov NCT04916002 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT04916002 |
추천 비교
추천 비교